
Recombinant Vaccines Market Share
Recombinant Vaccines Market Research Report Information: By Product (Subunit Recombinant and Attenuated Recombinant Vaccines), by Disease (Cancer, Pneumococcal Disease, Hepatitis B, and DPT), and End-Users (Pediatrics, Adults, and Veterinary) - Global Forecast Till 2035

Market Summary
The Global Recombinant Vaccines Market is projected to experience substantial growth from 0.36 USD Billion in 2024 to 1.94 USD Billion by 2035.
Key Market Trends & Highlights
Global Recombinant Vaccines Key Trends and Highlights
- The market is expected to grow at a compound annual growth rate of 16.56% from 2025 to 2035.
- By 2035, the market valuation is anticipated to reach 1.94 USD Billion, indicating robust expansion.
- In 2024, the market is valued at 0.36 USD Billion, highlighting its current size and potential for growth.
- Growing adoption of recombinant vaccine technology due to increasing awareness of vaccine-preventable diseases is a major market driver.
Market Size & Forecast
2024 Market Size | 0.36 (USD Billion) |
2035 Market Size | 1.94 (USD Billion) |
CAGR (2025-2035) | 16.56% |
Largest Regional Market Share in 2024 | latin_america) |
Major Players
Abiomed, Emergent Bio Solutions, Inc., GlaxoSmithKline, Johnson & Johnson, Sanofi Pasteur SA, Serum Institute of India Pvt. Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo, Pfizer, Inc.
Market Trends
The ongoing advancements in biotechnology are likely to enhance the efficacy and accessibility of recombinant vaccines, thereby playing a crucial role in global health initiatives.
World Health Organization (WHO)
Recombinant Vaccines Market Market Drivers
Market Growth Projections
Government Initiatives and Funding
Government initiatives and funding significantly influence the Global Recombinant Vaccines Market Industry. Many countries are increasing their investments in vaccine research and development to combat infectious diseases. For example, national health agencies are allocating substantial budgets to support the development of recombinant vaccines, which are often seen as a cost-effective solution for public health challenges. These initiatives not only facilitate the advancement of vaccine technology but also encourage collaboration between public and private sectors. As governments recognize the critical role of vaccines in safeguarding public health, the financial backing for recombinant vaccine projects is expected to grow, thereby enhancing the market landscape.
Rising Demand for Preventive Healthcare
The Global Recombinant Vaccines Market Industry experiences a notable surge in demand for preventive healthcare solutions. As populations become increasingly aware of the importance of vaccination in preventing infectious diseases, the market is projected to grow from 0.36 USD Billion in 2024 to an estimated 1.94 USD Billion by 2035. This growth indicates a compound annual growth rate (CAGR) of 16.56% from 2025 to 2035. Governments and health organizations are actively promoting vaccination programs, which further drives the demand for recombinant vaccines. This trend reflects a broader shift towards proactive health management, underscoring the significance of vaccines in public health strategies.
Increasing Incidence of Infectious Diseases
The rising incidence of infectious diseases is a crucial driver of the Global Recombinant Vaccines Market Industry. With the emergence of new pathogens and the resurgence of previously controlled diseases, the need for effective vaccination strategies has never been more pressing. This trend is particularly evident in regions experiencing outbreaks, where recombinant vaccines can provide rapid responses to emerging health threats. The World Health Organization and other health bodies emphasize the importance of vaccination in controlling disease spread. Consequently, the demand for recombinant vaccines is likely to increase, as they offer a viable solution to mitigate the impact of infectious diseases on global health.
Technological Advancements in Vaccine Development
Technological innovations play a pivotal role in shaping the Global Recombinant Vaccines Market Industry. Advances in genetic engineering and biotechnology have streamlined the development of recombinant vaccines, enhancing their efficacy and safety profiles. For instance, the use of recombinant DNA technology allows for the rapid production of vaccines tailored to specific pathogens. This capability not only accelerates the vaccine development process but also ensures a more robust immune response. As research institutions and pharmaceutical companies continue to invest in these technologies, the market is likely to witness an influx of novel vaccines, further propelling its growth and expanding the range of diseases that can be effectively targeted.
Growing Public Awareness and Acceptance of Vaccines
Public awareness and acceptance of vaccines are essential factors driving the Global Recombinant Vaccines Market Industry. Educational campaigns and outreach programs have significantly improved understanding of vaccine benefits, leading to higher vaccination rates. This trend is particularly evident in developing countries, where initiatives aimed at increasing vaccine literacy have resulted in greater public trust in vaccination programs. As communities become more informed about the role of vaccines in preventing diseases, the demand for recombinant vaccines is expected to rise. This growing acceptance not only supports public health objectives but also encourages investment in vaccine development, further stimulating market growth.
Market Segment Insights
Regional Insights
Key Companies in the Recombinant Vaccines Market market include




Industry Developments
Future Outlook
Recombinant Vaccines Market Future Outlook
The Global Recombinant Vaccines Market is projected to grow at a 16.56% CAGR from 2024 to 2035, driven by technological advancements, increasing disease prevalence, and rising healthcare investments.
New opportunities lie in:
- Develop novel adjuvants to enhance vaccine efficacy and market differentiation.
- Expand production capabilities in emerging markets to meet rising global demand.
- Invest in digital health solutions for vaccine distribution and patient engagement.
By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in global healthcare innovation.
Market Segmentation
Market Segmentation
Recombinant Vaccines Market Segmentation
Report Scope
Report Attribute/Metric | Details |
Market Size 2023 | 0.29 (USD Billion) |
Market Size 2024 | 0.36 (USD Billion) |
Market Size 2032 | 1.62 (USD Billion) |
Compound Annual Growth Rate (CAGR) | 6.24 % (2024 - 2032) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Base Year | 2023 |
Market Forecast Period | 2024 - 2032 |
Historical Data | 2019 - 2023 |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Abiomed, Emergent Bio Solutions, Inc., GlaxoSmithKline, Johnson & Johnson, Sanofi Pasteur SA, Serum Institute of India Pvt. Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo, Pfizer, Inc. |
Key Market Opportunities | · Raising awareness of healthcare, favorable reimbursement policies · Increasing innovations in research and development of drugs, and vaccines · Rising average income of individuals |
Key Market Drivers | · Increasing technical advanced devices · Increasing number of regulatory approvals · The high prevalence of infectious diseases · Growing penetration of key market players |
Market Highlights
Author
Latest Comments
This is a great article! Really helped me understand the topic better.
Thanks for sharing this. I’ve bookmarked it for later reference.
FAQs
What is the growth rate of the global recombinant vaccines market?
The global recombinant vaccines market is expected to expand at 6.24% CAGR from 2024 to 2032.
Who are the major players of the global recombinant vaccines market?
Mitsubishi Tanabe Pharma Corporation, Johnson & Johnson, Pfizer, Inc., GlaxoSmithKline, Daiichi Sankyo, Serum Institute of India Pvt. Ltd, Emergent Bio Solutions, Inc., Sanofi Pasteur SA, and Abiomed are major players in the global recombinant vaccines market.
What are the restraining factors of the global recombinant vaccines market?
High costs of vaccines and huge risks associated with attenuated vaccines are factors which can hamper the global recombinant vaccines market.
Which region can dominate in the global recombinant vaccines market?
The global recombinant vaccines market is led by the Americas due to rapid strides in molecular biology in the region.
What are major drivers of the global recombinant vaccines market?
High prevalence of diseases and large number of approvals are major drivers of the global recombinant vaccines market.
-
Table of Content
-
Report Prologue
-
Market Introduction
- Definition
-
Scope of the Study
- Research Objective
- Assumptions
- Limitations
-
Research Methodology
- Introduction
- Primary Research
- Secondary Research
- Market Size Estimation
-
Market Dynamics
- Drivers
- Restraints
- Opportunities
- Challenges
- Macroeconomic Indicators
- Technology Trends & Assessment
-
Market Factor Analysis
-
Porter’s Five Forces Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of New Entrants
- Threat of Substitutes
- Intensity of Rivalry
- Value Chain Analysis
- Investment Feasibility Analysis
- Pricing Analysis
-
Porter’s Five Forces Analysis
-
Global Recombinant Vaccines Market, by Route of Administration
-
6.1 Introduction
- Intramuscular and Subcutaneous Administration
-
• Market Estimates & Forecast, 2020–2027
-
• Market Estimates & Forecast, by Region/Country, 2020–2027
-
6.3 Oral Administration
-
• Market Estimates & Forecast, 2020–2027
-
• Market Estimates & Forecast, by Region/Country, 2020–2027
-
6.4 Other Routes of Administration
-
Global Recombinant Vaccines Market, by Type
- Introduction
- Subunit recombinant vaccines
-
• Market Estimates & Forecast, 2020–2027
- Attenuated recombinant vaccines
-
• Market Estimates & Forecast, 2020–2027
-
• Market Estimates & Forecast, by Region/Country, 2020–2027
-
7.4 Vector recombinant vaccines
-
• Market Estimates & Forecast, 2020–2027
-
• Market Estimates & Forecast, by Region/Country, 2020–2027
-
Global Recombinant Vaccines Market, by Disease
- Introduction
- Pneumococcal Disease
-
• Market Estimates & Forecast, 2020–2027
- Cancer
- Hepatitis B
- Influenza
-
8.6 HPV (Human papillomavirus)
-
• Market Estimates & Forecast, 2020–2027
-
• Market Estimates & Forecast, by Region/Country, 2020–2027
-
8.7 DPT
-
8.8 Others
-
• Market Estimates & Forecast, 2020–2027
-
• Market Estimates & Forecast, by Region/Country, 2020–2027
-
Global Recombinant Vaccines Market, by End-User
- Introduction
- Hospitals & Clinics
- Pediatrics
- Adults
-
9.5 Veterinary
-
• Market Estimates & Forecast, 2020–2027
-
• Market Estimates & Forecast, by Region/Country, 2020–2027
-
9.5.1 Poultry
-
9.5.2 Livestock
-
• Market Estimates & Forecast, by Region/Country, 2020–2027
- Others
-
10 Global Recombinant Vaccines Market, by Region
- Introduction
- Americas
-
• Market Estimates & Forecast, by Region, 2020–2027
-
• Market Estimates & Forecast, by Type, 2020–2027
-
• Market Estimates & Forecast, by Disease, 2020–2027
-
• Market Estimates & Forecast, by End-User, 2020–2027
- North America
-
• Market Estimates & Forecast, by Country, 2020–2027
-
• Market Estimates & Forecast, by Type, 2020–2027
-
• Market Estimates & Forecast, by Disease, 2020–2027
-
• Market Estimates & Forecast, by End-User, 2020–2027
- U.S.
-
• Market Estimates & Forecast, by Type, 2020–2027
-
• Market Estimates & Forecast, by Disease, 2020–2027
-
• Market Estimates & Forecast, by End-User, 2020–2027
- Canada
-
• Market Estimates & Forecast, by Type, 2020–2027
-
• Market Estimates & Forecast, by Disease, 2020–2027
-
• Market Estimates & Forecast, by End-User, 2020–2027
- South America
-
• Market Estimates & Forecast, by Type, 2020–2027
- Europe
-
• Market Estimates & Forecast, by Region, 2020–2027
- Western Europe
-
• Market Estimates & Forecast, by Country, 2020–2027
-
• Market Estimates & Forecast, by Type, 2020–2027
-
• Market Estimates & Forecast, by Disease, 2020–2027
- Germany
-
• Market Estimates & Forecast, by Type, 2020–2027
-
• Market Estimates & Forecast, by Disease, 2020–2027
-
• Market Estimates & Forecast, by End-User, 2020–2027
-
France
- U.K.
- Eastern Europe
-
France
-
• Market Estimates & Forecast, by Type, 2020–2027
- Asia Pacific
-
• Market Estimates & Forecast, by Country, 2020–2027
-
Japan
- China
- India
- Australia
- Republic of Korea
- Rest of Asia Pacific
-
Japan
-
• Market Estimates & Forecast, by Disease, 2020–2027
- The Middle East & Africa
-
• Market Estimates & Forecast, by Region, 2020–2027
-
United Arab Emirates
- Saudi Arabia
- Oman
- Kuwait
- Qatar
- Rest of the Middle East & Africa
-
United Arab Emirates
-
11 Company Landscape
- Introduction
- Market Share Analysis
-
Key Development & Strategies
- Key Developments
-
12 Company Profiles
-
Astellas Pharma Inc
- Company Overview
- Route of Administration Overview
- Financials
- SWOT Analysis
-
CSL Limited
- Company Overview
- Route of Administration Overview
- Financial Overview
- Key Developments
- SWOT Analysis
-
Emergent BioSolutions, Inc.
- Company Overview
- Route of Administration Overview
- Financial Overview
- Key Development
- SWOT Analysis
-
GlaxoSmithKline
- Company Overview
- Route of Administration/Business Segment Overview
- Financial Overview
- Key Development
- SWOT Analysis
-
Johnson & Johnson (U.S.)
- Company Overview
- Route of Administration Overview
- Financial overview
- Key Developments
-
Mitsubishi Tanabe Pharma Corporation
- Company Overview
- Route of Administration Overview
- Financial Overview
- Key Developments
-
Merck & Co., Inc.
- Overview
- Route of Administration Overview
- Financials
- Key Developments
- SWOT Analysis
-
Pfizer, Inc..
- Overview
- Route of Administration Overview
- Financials
- Key Developments
- SWOT Analysis
-
Sanofi Pasteur SA
- Overview
- Route of Administration Overview
- Financials
- Key Developments
- SWOT Analysis
-
Serum Institute of India Pvt. Ltd
- Overview
- Route of Administration Overview
- Financials
- Key Developments
- SWOT Analysis
-
Bavarian Nordic
- Overview
- Route of Administration Overview
- Financials
- Key Developments
- SWOT Analysis
-
Mitsubishi Tanabe Pharma Corporation
- Overview
- Route of Administration Overview
- Financials
- Key Developments
- SWOT Analysis
- Daiichi Sankyo
-
Astellas Pharma Inc
-
12.13.1 Overview
-
Route of Administration Overview
- Financials
- Key Developments
- SWOT Analysis
-
Route of Administration Overview
-
13 MRFR Conclusion
-
Key Findings
- From CEO’s View Point
- Unmet Needs of the Market
- Key Companies to Watch
- Prediction of Pharmaceutical Industry
-
Key Findings
-
14 Appendix
-
List of Tables and Figures
- LIST OF TABLES
- Table 1 Recombinant Vaccines Industry Synopsis, 2020–2027
- Table 2 Global Recombinant Vaccines Market Estimates and Forecast, 2020–2027, (USD Million)
- Table 3 Global Recombinant Vaccines Market by Region, 2020–2027, (USD Million)
- Table 5 Global Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
- Table 6 Global Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
- Table 7 Global Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
- Table 8 North America Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
- Table 9 North America Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
- Table 10 North America Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
- Table 11 US Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
- Table 12 US Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
- Table 13 US Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
- Table 14 Canada Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
- Table 15 Million)
- Table 16 Canada Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
- Table 17 Canada Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
- Table 18 South America Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
- Table 19 South America Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
- Table 20 South America Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
- Table 21 Europe Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
- Table 22 Europe Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
- Table 23 Europe Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
- Table 24 Western Europe Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
- Table 25 Western Europe Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
- Table 26 Western Europe Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
- Table 27 Eastern Europe Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
- Table 28 Eastern Europe Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
- Table 29 Eastern Europe Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
- Table 30 Asia Pacific Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
- Table 31 Asia Pacific Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
- Table 32 Asia Pacific Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
- Table 33 Middle East & Africa Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
- Table 34 Middle East & Africa Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million) LIST OF FIGURES
- Figure 1 Research Process
- Figure 2 Segmentation for Global Recombinant Vaccines Market
- Figure 3 Segmentation Market Dynamics for Recombinant Vaccines Market
- Figure 4 Global Recombinant Vaccines Market Share, by Type 2020
- Figure 5 Global Recombinant Vaccines Market Share, by End-Users, 2020
- Figure 6 Global Recombinant Vaccines Market Share, by Region, 2020
- Figure 7 North America Recombinant Vaccines Market Share, by Country, 2020
- Figure 8 Europe Recombinant Vaccines Market Share, by Country, 2020
- Figure 9 Asia Pacific Recombinant Vaccines Market Share, by Country, 2020
- Figure 10 Middle East & Africa Recombinant Vaccines Market Share, by Country, 2020
- Figure 11 Global Recombinant Vaccines Market: Company Share Analysis, 2020 (%)
- Figure 12 Astellas Pharma Inc: Key Financials
- Figure 13 Astellas Pharma Inc: Segmental Revenue
- Figure 14 Astellas Pharma Inc: Geographical Revenue
- Figure 15 Emergent BioSolutions, Inc.. Key Financials
- Figure 16 Emergent BioSolutions, Inc.: Segmental Revenue
- Figure 17 Emergent BioSolutions, Inc.: Geographical Revenue
- Figure 18 Pfizer, Inc.. : Key Financials
- Figure 19 Pfizer, Inc.. : Segmental Revenue
- Figure 20 Pfizer, Inc.. : Geographical Revenue
- Figure 21 GlaxoSmithKline: Key Financials
- Figure 22 GlaxoSmithKline: Segmental Revenue
- Figure 23 GlaxoSmithKline: Geographical Revenue
- Figure 24 Mitsubishi Tanabe Pharma Corporation : Key Financials
- Figure 25 Mitsubishi Tanabe Pharma Corporation : Segmental Revenue
- Figure 26 Mitsubishi Tanabe Pharma Corporation . Geographical Revenue
- Figure 29 Bavarian Nordic. Key Financials
- Figure 30 Bavarian Nordic. Segmental Revenue
- Figure 31 Bavarian Nordic. Geographical Revenue
Recombinant Vaccines Market Segmentation
Market Segmentation Overview
- Detailed segmentation data will be available in the full report
- Comprehensive analysis by multiple parameters
- Regional and country-level breakdowns
- Market size forecasts by segment

Free Sample Request
Kindly complete the form below to receive a free sample of this Report
Customer Strories
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Leave a Comment